Literature DB >> 15041116

A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.

Alexander von Keitz1, Jacob Rajfer, Scott Segal, Aileen Murphy, Jonathan Denne, Timothy Costigan, Daniel Lockhart, Charles M Beasley, Jeffrey T Emmick.   

Abstract

PURPOSE: To assess patient preference for erectile dysfunction treatment between either sildenafil or tadalafil, each administered with their respective dosing instructions, and to evaluate preference for either sildenafil or tadalafil dosing instructions during tadalafil therapy.
METHODS: We conducted a randomized, double-blind, crossover study consisting of four treatment arms. Because the dosing instructions for sildenafil and tadalafil are different, a unique methodology using sham placebo arms was employed to maintain the blind. To assess drug preference, 219 patients were randomized to either sildenafil 50 mg or tadalafil 20 mg, with dosing instructions reflecting their respective product profiles. To assess dosing instruction preference during tadalafil therapy, 46 patients were randomized to tadalafil 20 mg with either tadalafil or sildenafil dosing instructions. After 12 weeks, patients were crossed-over. After 4 weeks of each treatment, all patients following sildenafil dosing instructions were offered the opportunity for an upward dose titration. In a double-blind fashion, all patients who requested an upward titration received additional capsules. To mimic the pattern of dose usage observed in clinical practice, the number of patients who received additional double-blind active medication was limited to 35% of patients taking sildenafil in each treatment period in each country. Following the crossover treatment period, patients chose their preferred double-blind treatment with dosing instructions to receive in the 12-week extension period.
RESULTS: In the drug preference assessment, 132 of 181 (73%) evaluable patients chose to receive tadalafil (p < 0.001) during the extension period. In the dosing instruction preference assessment, 24 of 36 (67%) evaluable patients preferred tadalafil with tadalafil dosing instructions (p = 0.046). Sildenafil and tadalafil were well tolerated.
CONCLUSIONS: In the doses utilized in this study, 73% of patients preferred tadalafil with tadalafil dosing instructions for the treatment of their erectile dysfunction over sildenafil with sildenafil dosing instructions. During tadalafil therapy, 67% of patients preferred tadalafil dosing instructions over sildenafil dosing instructions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041116     DOI: 10.1016/j.eururo.2003.11.030

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  Initial experience with tadalafil in pediatric pulmonary arterial hypertension.

Authors:  Shinichi Takatsuki; Michelle Calderbank; David Dunbar Ivy
Journal:  Pediatr Cardiol       Date:  2012-03-09       Impact factor: 1.655

Review 2.  [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].

Authors:  H Porst
Journal:  Urologe A       Date:  2004-07       Impact factor: 0.639

Review 3.  An overview of the diagnosis and treatment of erectile dysfunction.

Authors:  Sivaprakasam Sivalingam; Hashim Hashim; Hartwig Schwaibold
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Management of erectile dysfunction in diabetes: an update for 2008.

Authors:  David Price; Geoffrey Hackett
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

Review 6.  The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Authors:  Jeremy A Falk; Kiran J Philip; Ernst R Schwarz
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

7.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

8.  Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.

Authors:  Ferdinando Fusco; Riccardo Sicuteri; Andrea Rossi; Stathis Kontodimas; Jose Maria Haro; Ciro Imbimbo; Vincenzo Mirone
Journal:  Asian J Androl       Date:  2009-08-24       Impact factor: 3.285

9.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.

Authors:  Amr Abdel Raheem; Philip Kell
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.